



BAFNA PHARMACEUTICALS LIMITED

REGD. OFFICE: "BAFNA TOWERS" 299 THAMBU CHETTY STREET, CHENNAI - 600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, Email: info@bafnapharma.com, Website: www.bafnapharma.com CIN: L24294
TN1995PLCO30698

BPL SE CS OFS 30/2023.

September 11, 2023.

To,

Listing Department, BSE Limited, P J Towers, Dalal Street, Mumbai – 400001.	Listing Department, National Stock Exchange of India, Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051.
Security Code: 532989 Security ID: BAFNAPHARM	Symbol: BAFNAPH Series: EQ.

Dear Sir/Madam,

Subject: Filing of report under Regulation 7(2)(b) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended (“SEBI Insider Trading Regulations”)

We hereby submit the attached disclosure received under Regulation 7(2)(a) of SEBI (PIT) Regulations, 2015, from SRJR Lifesciences LLP, one of the Promoters of Bafna Pharmaceuticals Limited (“the Company”), regarding disposal of the Equity Shares of the Company.

This submission is pursuant to Regulation 7(2)(b) of SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended.

This disclosure will also be made available on the website of the Company www.bafnapharma.com

Kindly take the above intimation on record.

Thank you,

Yours faithfully,
For Bafna Pharmaceuticals Limited,

(Vishnu V. Kuppa)
Company Secretary & Compliance Officer.

Encl.: As above.

SRJR LIFESCIENCES LLP

LLPIN: AAR-4517

ILABS CENTRE BUILDING NO.3, NO.18, SOFTWARE UNITS LAYOUT, MADHAPUR,
HYDERABAD, TELANGANA - 500 081

Date: September 11, 2023

To

Bafna Pharmaceuticals Limited

Bafna Towers, 299
Thambu Chetty Street
Chennai – 600 001
Tamil Nadu

Dear Sir/ Madam,

Sub: Filing of report under Regulation 7(2)(a) of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, as amended (“SEBI Insider Trading Regulations”).

This is with reference to the notice dated September 6, 2023 (“**Notice**”) filed by us with the Stock Exchanges, pursuant to which SRJR Lifesciences LLP, being the Promoter of Bafna Pharmaceuticals Limited (“**Company**”) proposed to sell up to 35,48,143 Equity Shares of the Company, (representing 15% of the total paid up equity share capital of the Company) (“**Offer Shares**”), on September 7, 2023, (“**T day**”) (for non-Retail Investors only) and on September 8, 2023 (“**T+1 day**”) (for Retail Investors and for non-Retail Investors who choose to carry forward their un-allotted bids) through a separate, designated window of the BSE Limited (the “**BSE**”) and the National Stock Exchange of India Limited (“**NSE**”, and together with the BSE, the “**Stock Exchanges**”), by way of an offer for sale through “*Comprehensive Framework on Offer for Sale of Shares through Stock Exchange Mechanism*” issued by the Securities and Exchange Board of India (“**SEBI**”) through its circular no. SEBI/HO/MRD/MRD-PoD-3/P/CIR/2023/10 dated January 10, 2023 (the “**OFS Circular**”), and section 21 of chapter 1 of the “*Master Circular for Stock Exchange and Clearing Corporation- Trading*” issued by SEBI through its circular no. SEBI/HO/MRD2/MRD2_DCAP/P/CIR/2021/0000000591 dated July 5, 2021 read with (a) “*Revised Operational Guidelines for Offer for Sale (OFS) Segment*” issued by BSE by way of its notice bearing no. 20230127-14 dated January 27, 2023 and, to the extent applicable, the previous circulars issued by BSE in this regard; (b) “*Revised operating guidelines of Offer for Sale*” issued by NSE by way of its circular bearing no. NSE/CMTR/55432 and dated January 31, 2023 to the extent applicable, the previous notices issued by NSE in this regard (together with the OFS Circular, the “**SEBI OFS Guidelines**”), and such offer for sale is referred to as the “**Offer**”.

In this regard, we wish to inform you that we have sold 1,57,248 Equity Shares to non-retail investors on the basis of the valid bids received from non-retail investors on T Day i.e., September 7, 2023 and sold 1,41,418 Equity Shares to retail investors on T+1 day i.e., on September 8, 2023, in aggregate, amounting to 1.26% of the equity share capital of the Company.

In compliance with Regulation 7(2)(a) of the SEBI Insider Trading Regulations, we are hereby notifying the Company of the information regarding disposal of the Equity Shares within 2 trading days of such transactions.

Enclosed is the report in the format prescribed in Form C of the circular bearing number SEBI/HO/ISD/ISD/CIR/P/2021/19 dated February 9, 2021, issued by the Securities and Exchange Board of India.


The above is for your information and records.

Yours sincerely,

On behalf of SRJR Lifesciences LLP



Seshadri Rangarajan
Authorised Signatory



FORM C

**Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015
[Regulation 7(2) read with Regulation 6(2) - Continual Disclosure]**

Name of the company: Bafna Pharmaceuticals Limited

ISIN of the company: INE878101022

Details of change in holding of Securities of Promoter, Member of the Promoter Group, Designated Person or Director of a listed company and immediate relatives of such persons and other such persons as mentioned in Regulation 6(2).

1 Name, PAN, CIN/DIN, & address with contact nos.	2 Category of Person (Promote r/member of the promoter group/ designate d person/ Directors/ Immediat e relatives/ others etc.)	3 Securities held prior to disposal		4 Securities Disposed			5 Securities held post acquisition/disposal		6 Date of intimatio n to company	7 Mode of acquisition/ disposal (on market/publi c/ rights/ preferential offer / off market/ Inter-se transfer, ESOPs etc.)	8 Exchange on which the trade was executed		
		Type of Security (For eg. - Shars, War ants, Con ert ible Debentu res, Rights entitlem ents etc.)	No. and % of shareholdin g	No.	Value	Transacti on type (Purchase/ Sale/ Pledge/ Revocatio n/ Invocation / Others - please specify)	Type of securiti es (For eg. - Shars, War ants, Con ert ible Debent ures, Rights entitlem ents etc.)	No. and % of shareholdin g				Date of allotment advice/ acquisition of shares/ disposal of shares/ specify From To	
1									11	12	13	14	15

Name: SRJR Lifescience s LLP ("Promoter ") PAN: AECFS120 8Q Address: iLabs Centre, Building No. 3, No. 18, Software Units Layout, Madhapur, Hyderabad, Telangana - 500081 Contact No. +91 70326 39418	Promoter	Equity Shares	2,11,88,159 Equity Shares and 89.57% of the paid-up equity share capital of the Company	Equity Shares	1,57,248 Equity Shares (0.66% of the paid-up Equity Shares) ⁽¹⁾	₹ 1,41,25,276.8 8 ⁽²⁾	Offer for Sale of Equity Shares by the Promoter through the stock exchange mechanism	Equity Shares	2,10,30,911 Equity Shares and 88.90% of the paid-up equity share capital of the Company	Sept emb er 7, 2023	Sept tem ber 7, 2023	September 11, 2023	On market through an Offer For Sale of Equity Shares by the Promoter through the stock exchange mechanism	BSE & NSE (Trade was executed on both the exchange s)
Name: SRJR Lifescience s LLP ("Promoter ") PAN: AECFS120 8Q Address: iLabs Centre,	Promoter	Equity Shares	2,10,30,911 Equity Shares and 88.90% of the paid-up equity share capital of the Company	Equity Shares	1,41,418 Equity Shares (0.60% of the paid-up Equity Shares) ⁽³⁾	₹1,24,19,549. 71 ⁽⁴⁾	Offer for Sale of Equity Shares by the Promoter through the stock exchange mechanism	Equity Shares	2,08,89,493 Equity Shares and 88.30% of the paid-up equity share capital of the Company	Sept emb er 8, 2023	Sept tem ber 8, 2023	September 11, 2023	On market, through Offer For Sale of Equity Shares by the Promoter through the stock exchange mechanism	BSE & NSE (Trade was executed on both the exchange s)

